Genes News and Research

RSS

Dyslexia gene linked to concussion susceptibility in athletes

A gene associated with dyslexia, a learning disorder, may make some athletes less susceptible to concussions, reports a new study from Penn State University and Northwestern Medicine.

24 Oct 2018

Innovative computer software sheds new light on genetic processes underlying deadly diseases

Innovative computer software developed by University of Leicester scientists is shedding new light on the genetic makeup of deadly pathogens responsible for meningitis and gastroenteritis.

23 Oct 2018

Gut bacterial community of healthy adults recovers after short-term exposure to broad-spectrum antibiotics

The trillions of bacteria in the human gut affect our health in multiple ways including effects on immune functions and metabolism.

23 Oct 2018

New type of molecule shows early promise against treatment-resistant prostate cancer

A new type of molecule blocks the action of genes that drive the growth of therapy-resistant prostate cancer, a new study finds.

23 Oct 2018

Map of human liver cells reveals molecular make-up of individual cells

A map of the cells in the human liver has been created by University Health Network Transplant Program and University of Toronto researchers, revealing for the first time differences between individual cells at the molecular level which can have a profound impact on their behaviour in tissue, tumours and disease.

From 10x Genomics, Inc. 23 Oct 2018

New discovery may lead to better treatment options for pancreatic cancer patients

Pancreatic cancer is one of the most difficult cancers to treat and is a leading cause of cancer-related deaths. Now, Sidney Kimmel Cancer Center - Jefferson Health and Lankenau Institute for Medical Research scientists find that a gene involved in the immune system called IDO2 plays a significant role in pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer.

23 Oct 2018

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.

23 Oct 2018

New approach may lead to better diagnostic techniques for autoimmune disorders

If we really want to know how our body's cells work - or don't work, in the case of disease - we might need to look beyond their genes and even beyond the proteins they are made of.

23 Oct 2018

Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

Researchers from The Ottawa Hospital and the University of Ottawa have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia and a diagnostic test to determine which AML patients would most likely benefit from this treatment.

22 Oct 2018

Targeted drug and hormone therapy combination extends breast cancer survival

Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer, a major clinical trial has found.

22 Oct 2018

Epigenetic modifications may contribute to Alzheimer's Disease

Scientists report epigenetic modifications in the brains of patients with Alzheimer's, after observing differences in histone acetylation across the genome.

22 Oct 2018

IDT to demonstrate CRISPR expertise at European-focused events

As an advocate for the genomics age, Integrated DNA Technologies (IDT), will showcase its renowned CRISPR expertise at a series of European-focused events.

From Integrated DNA Technologies 22 Oct 2018

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation, results from the phase 3 SOLO-1 trial show.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for KALYDECO (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

22 Oct 2018

Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients

Epigenetic therapy with histone deacetylase inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial reported today at the ESMO 2018 Congress in Munich.

22 Oct 2018

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.

22 Oct 2018

Genes News and Research

Dyslexia gene linked to concussion susceptibility in athletes

Innovative computer software sheds new light on genetic processes underlying deadly diseases

Gut bacterial community of healthy adults recovers after short-term exposure to broad-spectrum antibiotics

New type of molecule shows early promise against treatment-resistant prostate cancer

Map of human liver cells reveals molecular make-up of individual cells

New discovery may lead to better treatment options for pancreatic cancer patients

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

New approach may lead to better diagnostic techniques for autoimmune disorders

Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

Targeted drug and hormone therapy combination extends breast cancer survival

Epigenetic modifications may contribute to Alzheimer's Disease

IDT to demonstrate CRISPR expertise at European-focused events

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics